SCHEMBL4877773

SCHEMBL4877773

COc1ccc(-c2ccc3cc(-c4c(C5CCCCC5)c5sc(C(=O)O)cc5n4CC(=O)N4CCC(N5CCOCC5)CC4)ccc3n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 2/20 0.38
CDYL2 Q8N8U2 2/20 0.38
CDYL Q9Y232 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
ACHE P22303 1/20 0.37
PIK3CA P42336 1/20 0.36
MTOR P42345 1/20 0.36
PTGS2 P35354 2/20 0.36
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 4/20 0.36
HPGD P15428 3/20 0.36
GAA P10253 1/20 0.36
SCN9A Q15858 1/20 0.35
ALOX15 P16050 1/20 0.35
HTT P42858 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.34
CDY1; CDY1B Q9Y6F8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4878172 0.94 PIK3CA (0.39) CBX7CDYL2CDYLACHEPIK3CA
SCHEMBL4870887 0.92 CBX7 (0.37) CBX7CDYL2CDYLL3MBTL1GRIN1
SCHEMBL4868463 0.91 KMT2A (0.39) L3MBTL1GRIN1GRIN2BPIK3CAMTOR
SCHEMBL4874058 0.91 ALDH1A1 (0.41) GRIN1GRIN2BPIK3CAMTORPTGS2
SCHEMBL4866862 0.90 KMT2A (0.36) L3MBTL1GRIN1GRIN2BPIK3CAMTOR
SCHEMBL4877781 0.89 ACHE (0.43) CBX7CDYL2CDYLL3MBTL1GRIN1
SCHEMBL4877158 0.89 PIK3CA (0.40) CBX7CDYL2CDYLACHEPIK3CA
SCHEMBL4877126 0.88 CBX7 (0.37) CBX7CDYL2CDYLGRIN2BACHE
SCHEMBL4873208 0.88 CBX7 (0.35) CBX7CDYL2CDYLACHEMTOR
SCHEMBL4874701 0.88 TP53 (0.36) CBX7CDYL2CDYLACHEKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 CBX7 2500/4885CDYL2 4283/4885CDYL 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.